Eye Inflammation Tied to Anti-Adalimumab Antibody Formation
A study found that over 20% of patients with autoimmune diseases receiving adalimumab developed antibodies against the drug. Ocular inflammation, female sex, and treatment interruptions were linked to a higher risk of antibody formation. The findings highlight the importance of monitoring treatment adherence, especially in at-risk populations.
- ▪Of 704 patients studied, 151 developed antibodies against adalimumab.
- ▪Ocular inflammation was associated with a 67% higher risk for antibody detection.
- ▪Female patients had higher odds of developing anti-adalimumab antibodies compared to male patients.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:In patients with autoimmune diseases who received adalimumab, more than one fifth developed antibodies against the drug. The presence of ocular inflammation, female sex, and treatment interruptions were independently associated with an increased risk of developing anti-adalimumab antibodies.METHODOLOGY:Researchers used data from the US-based Stanford Research Repository to conduct a retrospective case-control study of patients who received adalimumab for at least 6 months between June 2005 and May 2024.A total of 704 patients with various autoimmune conditions (mean age, 34.52 years; 50% men) who had at least one documented test for adalimumab drug levels and/or anti-adalimumab antibodies were included in the analysis.The collected data comprised demographics, systemic diagnoses,…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
